SpliceCore is Envisagenics' proprietary AI/ML platform that enables the translation of vast amounts of RNA sequencing data into novel therapeutics. SpliceCore's versatility extends to both the ...

The British drugmaker has bolstered its business with nearly $5 billion in acquisitions as attention turns to its pipeline of experimental medicines.

The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.

First quarter sales of Zurzuvae doubled consensus estimates, though analysts are skeptical whether the better-than-expected launch will continue.

An expanded partnership with OpenAI is helping Moderna embed custom-built AI chatbots in a wide range of research and business processes.

Led by the founder of a biotech Celgene acquired for $7 billion, the startup is developing two prospects that originated in the labs of other drugmakers.

The mRNA vaccine maker, which has lost most of its value since early 2021, is undergoing an “organizational redesign” that will eliminate 150 positions.

While the company is eager to diversify, CEO Chris Viehbacher said that in the near-term any dealmaking would likely focus on collaborations and early-stage assets.

Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise.

The complete response letter for Abeona’s treatment is one of several manufacturing setbacks for cell and gene therapy developers in recent years.

Giovanni Caforio, who left Bristol Myers in November after eight years as CEO, is set to succeed Novartis’ longtime board chair Joerg Reinhardt next year.

The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA.